DexCom, Inc. (NASDAQ:DXCM) VP Patrick Michael Murphy sold 2,372 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $143.69, for a total value of $340,832.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Patrick Michael Murphy also recently made the following trade(s):

  • On Friday, August 10th, Patrick Michael Murphy sold 12,500 shares of DexCom stock. The stock was sold at an average price of $124.18, for a total value of $1,552,250.00.

Shares of DXCM opened at $145.00 on Friday. DexCom, Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $148.56. The stock has a market cap of $12.92 billion, a PE ratio of -250.00 and a beta of 0.46. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.89 and a quick ratio of 4.62.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, August 1st. The medical device company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.08. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The business had revenue of $242.50 million during the quarter, compared to the consensus estimate of $205.81 million. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. The business’s quarterly revenue was up 42.1% compared to the same quarter last year. sell-side analysts anticipate that DexCom, Inc. will post -0.47 EPS for the current year.

Several equities analysts have issued reports on DXCM shares. BMO Capital Markets raised their price objective on DexCom to $112.00 and gave the stock an “outperform” rating in a report on Tuesday, July 10th. Piper Jaffray Companies raised their price objective on DexCom to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, June 12th. Bank of America raised their price objective on DexCom from $106.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, August 2nd. Berenberg Bank raised DexCom from a “hold” rating to a “buy” rating and set a $140.00 price objective on the stock in a report on Monday, August 6th. Finally, Jefferies Financial Group raised their price objective on DexCom from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $111.64.

Institutional investors and hedge funds have recently made changes to their positions in the company. Signaturefd LLC acquired a new stake in shares of DexCom during the first quarter worth about $105,000. Cerebellum GP LLC acquired a new stake in DexCom in the second quarter valued at about $171,000. SG Americas Securities LLC acquired a new stake in DexCom in the first quarter valued at about $175,000. Clinton Group Inc. acquired a new stake in DexCom in the second quarter valued at about $201,000. Finally, Bank Pictet & Cie Asia Ltd. acquired a new stake in DexCom in the second quarter valued at about $218,000.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: Return on Investment (ROI) Defined, Explained

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.